The aim of the current paper is to summarize the results of the International CytoSorb
Registry. Data were collected on patients of the intensive care unit. The primary
endpoint was actual in-hospital mortality compared to the mortality predicted by APACHE
II score. The main secondary endpoints were SOFA scores, inflammatory biomarkers and
overall evaluation of the general condition. 1434 patients were enrolled. Indications
for hemoadsorption were sepsis/septic shock (N = 936); cardiac surgery perioperatively
(N = 172); cardiac surgery postoperatively (N = 67) and "other" reasons (N = 259).
APACHE-II-predicted mortality was 62.0±24.8%, whereas observed hospital mortality
was 50.1%. Overall SOFA scores did not change but cardiovascular and pulmonary SOFA
scores decreased by 0.4 [-0.5;-0.3] and -0.2 [-0.3;-0.2] points, respectively. Serum
procalcitonin and C-reactive protein levels showed significant reduction: -15.4 [-19.6;-11.17]
ng/mL; -17,52 [-70;44] mg/L, respectively. In the septic cohort PCT and IL-6 also
showed significant reduction: -18.2 [-23.6;-12.8] ng/mL; -2.6 [-3.0;-2.2] pg/mL, respectively.
Evaluation of the overall effect: minimal improvement (22%), much improvement (22%)
and very much improvement (10%), no change observed (30%) and deterioration (4%).
There was no significant difference in the primary outcome of mortality, but there
were improvements in cardiovascular and pulmonary SOFA scores and a reduction in PCT,
CRP and IL-6 levels. Trial registration: ClinicalTrials.gov Identifier: NCT02312024
(retrospectively registered).
